VIDEO: ASAP trial 'could challenge standard of care' for relapsed/refractory AML

ByRichard M. Stone, MD

ByCory Perla

Fact checked byMindy Valcarcel, MS

NEW ORLEANS — In this video perspective, Richard M Stone, MD, discusses data from the randomized phase 3 ASAP trial, which was presented at ASH Annual Meeting and Exposition.

The data showed that high-dose cytarabine and mitoxantrone given prior to allogeneic hematopoietic cell transplantation did not result in a higher overall success rate vs. standard of care.

Stone, professor of medicine at Harvard Medical school and director of translation research in the adult leukemia program at Dana Farber Institute, said these results could challenge standard of care for relapsed and refractory acute myeloid leukemia.

"The results were equivalent in terms of overall survival, indicating that it wasn't a bad move to take people right to transplant," he said.

Reference:

Stelljes M, et al. Abstract 4. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Stone reports serving in consultancy roles for AbbVie, Astellas, Bristol Myers Squibb, BerGenBio, Boston Pharmaceuticals, Elevate Bio, Epizyme, Foghorn Therapeutics, GEMoaB, GSK, Innate, Janssen, Jazz, Kura Oncology, Novartis, OncoNova, Syndax, Syntrix and Syros.